Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants

计划入组 360 人 · 首次发布于 2023 年 1 月 4 日

Protein-bound Versus Free Amino Acid Nutrition During INtestinal Malabsorption in Critical Illness

计划入组 16 人 · 首次发布于 2021 年 3 月 10 日

Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA

计划入组 60 人 · 首次发布于 2023 年 6 月 15 日

Vasoactive intestinal peptide

C₁₄₇H₂₃₇N₄₃O₄₃S

Intestinal trefoil factor

Oral alkaline phosphatase (Synthetic Biologics)

AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP

Australia

GEDII - GRUPO DE ESTUDO DA DOENÇA INFLAMATÓRIA INTESTINAL

Portugal

Oncolytics Biotech Inc

Canada

Elgan Pharma and Chiesi Begin Phase 3 Trial of ELGN-2112 for Intestinal Malabsorption in Preterm Infants

Jaguar Health's Napo Therapeutics Advances Crofelemer for Rare Intestinal Diseases in Europe

Novel Mango-Flavored Pill Shows Promise in Eradicating Intestinal Worms